for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Soligenix Inc

SNGX.OQ

Latest Trade

1.92USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.66

 - 

3.50

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Soligenix Announces Recent Accomplishments And Q1 2020 Financial Results

May 15 (Reuters) - Soligenix Inc <SNGX.O>::SOLIGENIX ANNOUNCES RECENT ACCOMPLISHMENTS AND FIRST QUARTER 2020 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.32.Q1 REVENUE $900,000 VERSUS REFINITIV IBES ESTIMATE OF $750,000.Q1 EARNINGS PER SHARE ESTIMATE $-0.11 -- REFINITIV IBES DATA.SEES AS OF MARCH 31, 2020, COMPANY'S CASH POSITION WAS APPROXIMATELY $7.2 MILLION.

Soligenix Announces Positive Top-Line Results For Its Pivotal Phase 3 Flash Trial Evaluating Sgx301 In Treatment Of Cutaneous T-Cell Lymphoma

March 19 (Reuters) - Soligenix Inc <SNGX.O>::SOLIGENIX ANNOUNCES POSITIVE TOP-LINE RESULTS FOR ITS PIVOTAL PHASE 3 FLASH TRIAL EVALUATING SGX301 IN TREATMENT OF CUTANEOUS T-CELL LYMPHOMA.SOLIGENIX INC - STATISTICALLY SIGNIFICANT TREATMENT RESPONSE ACHIEVED IN PRIMARY ENDPOINT OF SGX301.SOLIGENIX INC - SGX301 WAS WELL-TOLERATED AND ITS MECHANISM OF ACTION IS NOT ASSOCIATED WITH DNA DAMAGE LIKE OTHER CURRENTLY AVAILABLE THERAPIES.

FDA Grants Soligenix "Fast Track" Designation For Rivax In The Prevention Of Ricin Poisoning

Feb 13 (Reuters) - Soligenix Inc <SNGX.O>::FDA GRANTS SOLIGENIX "FAST TRACK" DESIGNATION FOR RIVAX® IN THE PREVENTION OF RICIN POISONING.

Soligenix Initiates Clinical Trial Of Its Heat Stable Ricin Toxin Vaccine

Dec 12 (Reuters) - Soligenix Inc <SNGX.O>::SOLIGENIX INITIATES CLINICAL TRIAL OF ITS HEAT STABLE RICIN TOXIN VACCINE.SOLIGENIX INC - PRELIMINARY SAFETY RESULTS FROM TRIAL OF HEAT STABLE RICIN TOXIN VACCINE ARE EXPECTED IN Q2 OF 2020.SOLIGENIX - IMMUNOGENICITY RESULTS FROM HEAT STABLE RICIN TOXIN VACCINE TRIAL THROUGHOUT 6-MONTH FOLLOW-UP PERIOD EXPECTED IN Q4 2020.

Soligenix Appoints Jonathan Guarino As Chief Financial Officer

Sept 11 (Reuters) - Soligenix Inc <SNGX.O>::SOLIGENIX APPOINTS JONATHAN GUARINO AS CHIEF FINANCIAL OFFICER.SOLIGENIX - KAREN KRUMEICH, WHO SERVED CFO, WILL BE PURSUING NEW OPPORTUNITIES EFFECTIVE SEPTEMBER 6.SOLIGENIX INC - MOST RECENTLY, GUARINO SERVED AS CORPORATE CONTROLLER FOR HEPION PHARMACEUTICALS, INC.

Soligenix Announces Positive Recommendation On Its Phase 3 Clinical Trial For Treatment Of Oral Mucositis In Head And Neck Cancer

Aug 28 (Reuters) - Soligenix Inc <SNGX.O>::SOLIGENIX ANNOUNCES POSITIVE RECOMMENDATION BY INDEPENDENT DATA MONITORING COMMITTEE ON ITS PHASE 3 CLINICAL TRIAL OF SGX942 FOR THE TREATMENT OF ORAL MUCOSITIS IN HEAD AND NECK CANCER.SOLIGENIX INC - FINAL TOPLINE RESULTS REMAIN ON TARGET FOR FIRST HALF 2020.SOLIGENIX INC - FINAL TOPLINE RESULTS REMAIN ON TARGET FOR FIRST HALF 2020.SOLIGENIX INC - NO SAFETY CONCERNS WERE REPORTED BY DMC BASED ON INTERIM ANALYSIS.

Soligenix Q2 Loss Per Share $0.12

Soligenix Inc <SNGX.O>::SOLIGENIX ANNOUNCES RECENT ACCOMPLISHMENTS AND SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.12.Q2 REVENUE $1.5 MILLION VERSUS $1.7 MILLION.Q2 REVENUE ESTIMATE $833,000 -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE ESTIMATE $-0.14 -- REFINITIV IBES DATA.AS OF JUNE 30, 2019, COMPANY'S CASH POSITION WAS APPROXIMATELY $7.0 MILLION.

Soligenix Q1 Loss Per Share $0.09

Soligenix Inc <SNGX.O>::SOLIGENIX ANNOUNCES RECENT ACCOMPLISHMENTS AND FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.09.REVENUES FOR QUARTERS ENDED MARCH 31, 2019 AND 2018 WERE EACH $1.1 MILLION.QTRLY BASIC LOSS PER SHARE $0.09.SOLIGENIX - AS OF MARCH 31, CO'S CASH POSITION WAS ABOUT $7.2 MILLION.

Soligenix Says DMC Interim Analysis For Phase 3 Trial Of SGX942 Is Anticipated In Sept

April 23 (Reuters) - Soligenix Inc <SNGX.O>::SOLIGENIX -- ADVANCING TO IMPORTANT INFLECTION POINTS WITH TWO PIVOTAL PHASE 3 CLINICAL TRIALS.SOLIGENIX INC - COMPANY PROVIDES Q1 2019 UPDATE AND GUIDANCE.SOLIGENIX INC - ACTIVELY ENROLLING PATIENTS IN OUR PIVOTAL PHASE 3 DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN CTCL WITH SGX301.SOLIGENIX INC - ANTICIPATE COMPLETING STUDY ENROLLMENT IN SECOND HALF OF 2019, WITH FINAL TOP-LINE RESULTS NO LATER THAN Q1 2020 ON "FLASH" STUDY.SOLIGENIX INC - DMC INTERIM ANALYSIS FOR PHASE 3 TRIAL OF SGX942 IS CURRENTLY ANTICIPATED TO OCCUR IN SEPTEMBER 2019.SOLIGENIX INC - ANTICIPATE INITIATING A PHASE 2 VACCINE IMMUNOGENICITY AND SAFETY STUDY IN HEALTHY VOLUNTEERS UTILIZING RIVAX IN SECOND HALF OF 2019.

Soligenix And The European Medicines Agency Pediatric Committee Reach Agreement On The Pediatric Investigation Plan For SGX942

April 9 (Reuters) - Soligenix Inc <SNGX.O>::SOLIGENIX AND THE EUROPEAN MEDICINES AGENCY PEDIATRIC COMMITTEE REACH AGREEMENT ON THE PEDIATRIC INVESTIGATION PLAN FOR SGX942.SOLIGENIX INC - ACCEPTANCE OF PEDIATRIC INVESTIGATION PLAN IS IMPORTANT MILESTONE ON PATH TO SUBMISSION OF MARKETING AUTHORIZATION APPLICATION IN EUROPE.SOLIGENIX INC - PATIENT RECRUITMENT IS ANTICIPATED TO BE COMPLETED IN 2019 WITH TOP-LINE RESULTS AVAILABLE IN FIRST HALF OF 2020.SOLIGENIX INC - TO ADVANCE DUSQUETIDE DEVELOPMENT WITH CONDUCT OF A PHASE 3 CLINICAL TRIAL REFERRED TO AS "DOM-INNATE" STUDY.SOLIGENIX - MAY DEFER CONDUCTING PIP TILL SUCCESSFUL COMPLETION OF ONGOING PIVOTAL PHASE 3 CLINICAL STUDY EVALUATING SGX942 AS TREATMENT FOR ORAL MUCOSITIS.SOLIGENIX INC - FOLLOWING A POTENTIAL APPROVAL OF SGX942 MAA, WILL WORK WITH PDCO & EMA TO INCLUDE APPROPRIATE PEDIATRIC DATA IN APPROVED LABELING.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up